These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
874 related articles for article (PubMed ID: 16020489)
1. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489 [TBL] [Abstract][Full Text] [Related]
2. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346 [TBL] [Abstract][Full Text] [Related]
3. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome]. Tegaserod Clinical Research Group Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702 [TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Nyhlin H; Bang C; Elsborg L; Silvennoinen J; Holme I; Rüegg P; Jones J; Wagner A Scand J Gastroenterol; 2004 Feb; 39(2):119-26. PubMed ID: 15000272 [TBL] [Abstract][Full Text] [Related]
5. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Reilly MC; Barghout V; McBurney CR; Niecko TE Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674 [TBL] [Abstract][Full Text] [Related]
6. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659 [TBL] [Abstract][Full Text] [Related]
7. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Evans BW; Clark WK; Moore DJ; Whorwell PJ Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807 [TBL] [Abstract][Full Text] [Related]
8. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care. Layer P; Keller J; Mueller-Lissner S; Rüegg P; Loeffler H Digestion; 2005; 71(4):238-44. PubMed ID: 16024929 [TBL] [Abstract][Full Text] [Related]
9. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study. Bardhan KD; Forbes A; Marsden CL; Mason T; Short G Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702 [TBL] [Abstract][Full Text] [Related]
10. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. Tack JF; Miner PB; Fischer L; Harris MS Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096 [TBL] [Abstract][Full Text] [Related]
13. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040 [TBL] [Abstract][Full Text] [Related]
14. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Gale JD Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393 [TBL] [Abstract][Full Text] [Related]
15. Tegaserod for constipation-predominant irritable bowel syndrome. Kale-Pradhan PB; Wilhelm SM Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916 [TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation. Fock KM; Wagner A; J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039 [TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208 [TBL] [Abstract][Full Text] [Related]
18. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494 [TBL] [Abstract][Full Text] [Related]
19. Tegaserod for the treatment of irritable bowel syndrome. Evans BW; Clark WK; Moore DJ; Whorwell PJ Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049 [TBL] [Abstract][Full Text] [Related]
20. [Tegaserod in treatment of women with irritable bowel syndrome]. Munck LK; Ainsworth MA Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]